Pasithea Therapeutics Corp Financials
This page shows Pasithea Therapeutics Corp (KTTAW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash replenishment from financing, not operations, is the dominant mechanic as recurring losses are carried on an unleveraged balance sheet.
From FY2023 to FY2025, cash fell to$6.9M and then jumped to$55.2M only after financing inflow of$63.5M . Over the same three years, operating cash outflow totaled about$42.0M , which means liquidity was rebuilt by new capital rather than by any self-funding operating cycle.
FY2025 net loss of
The cost structure is now more overhead-heavy than purely research-led: FY2025 SG&A reached
Financial Health Signals
Pasithea Therapeutics Corp does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Pasithea Therapeutics Corp passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Pasithea Therapeutics Corp reported a net loss of $20.4M while operations used $15.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Pasithea Therapeutics Corp's EBITDA was -$20.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 46.3% from the prior year.
Pasithea Therapeutics Corp reported -$20.4M in net income in fiscal year 2025. This represents a decrease of 46.9% from the prior year.
Pasithea Therapeutics Corp earned -$2.91 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Pasithea Therapeutics Corp held $55.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Pasithea Therapeutics Corp's ROE was -37.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 57.1 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Pasithea Therapeutics Corp invested $8.0M in research and development in fiscal year 2025. This represents an increase of 10.9% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
KTTAW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $487K+3130.4% | $15K |
| Cost of Revenue | N/A | N/A | N/A | N/A | $113K+555.3% | $17K |
| Gross Profit | N/A | N/A | N/A | N/A | $373K+16971.4% | -$2K |
| R&D Expenses | N/A | $8.0M+10.9% | $7.2M-11.1% | $8.1M+203.9% | $2.7M | N/A |
| SG&A Expenses | N/A | $12.9M+82.6% | $7.1M-10.5% | $7.9M-20.6% | $9.9M+120.3% | $4.5M |
| Operating Income | N/A | -$20.9M-46.4% | -$14.2M+10.8% | -$16.0M-26.9% | -$12.6M-179.3% | -$4.5M |
| Interest Expense | N/A | N/A | N/A | N/A | $102-79.9% | $508 |
| Net Income | N/A | -$20.4M-46.9% | -$13.9M+12.9% | -$16.0M-14.5% | -$13.9M-541.2% | -$2.2M |
| EPS (Diluted) | — | -$2.91 | -$12.69 | -$0.42 | -$1.76-738.1% | -$0.21 |
Not reported in any period shown, so not listed: Income Tax.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
KTTAW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Total Assets | $60.2M+275.0% | $16.1M-38.5% | $26.1M-42.2% | $45.2M-15.3% | $53.3M |
| Current Assets | $56.5M+666.2% | $7.4M-55.9% | $16.7M-51.0% | $34.1M-36.1% | $53.3M |
| Cash & Equivalents | $55.2M+696.8% | $6.9M-57.6% | $16.3M-50.6% | $33.1M-37.5% | $53.0M |
| Goodwill | N/A | $1.3M0.0% | $1.3M0.0% | $1.3M | N/A |
| Total Liabilities | $5.0M+291.6% | $1.3M-52.8% | $2.7M+1.4% | $2.7M+41.1% | $1.9M |
| Current Liabilities | $5.0M+344.2% | $1.1M-57.5% | $2.6M+40.3% | $1.9M+319.8% | $447K |
| Total Equity | $55.2M+273.5% | $14.8M-36.8% | $23.4M-44.9% | $42.5M-17.4% | $51.4M |
| Retained Earnings | -$70.0M-41.2% | -$49.6M-40.4% | -$35.3M-82.5% | -$19.4M-774.1% | -$2.2M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.
KTTAW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$17.8M | -$15.2M-9.3% | -$13.9M-8.7% | -$12.8M+12.0% | -$14.6M-358.8% | -$3.2M |
| Capital Expenditures | N/A | N/A | N/A | $34K-68.0% | $107K+398.1% | $22K |
| Free Cash Flow | N/A | N/A | N/A | -$12.8M+12.4% | -$14.7M-359.0% | -$3.2M |
| Investing Cash Flow | N/A | $11K | N/A | N/A | -$2.1M-9487.2% | -$22K |
| Financing Cash Flow | $56.3M | $63.5M+1306.0% | $4.5M | N/A | -$3.2M-105.7% | $55.9M |
| Share Buybacks | N/A | N/A | N/A | $3.7M | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
KTTAW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | 76.7%+91.4pp | -14.7% |
| Operating Margin | N/A | N/A | N/A | -2587.3% | -29925.7% |
| Net Margin | N/A | N/A | N/A | -2864.3% | -14430.5% |
| Return on Equity | -37.0%+57.1pp | -94.1%-25.8pp | -68.2%-35.4pp | -32.8%-28.6pp | -4.2% |
| Return on Assets | -33.9%+52.6pp | -86.6%-25.4pp | -61.1%-30.3pp | -30.9%-26.8pp | -4.1% |
| Current Ratio | 11.35+4.8x | 6.58+0.2x | 6.34-11.8x | 18.15-101.0x | 119.17 |
| Debt-to-Equity | 0.090.0x | 0.090.0x | 0.12+0.1x | 0.060.0x | 0.04 |
| FCF Margin | N/A | N/A | N/A | -3014.8% | -21216.1% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Pasithea Therapeutics Corp Ranks
Frequently Asked Questions
Is Pasithea Therapeutics Corp profitable?
No, Pasithea Therapeutics Corp (KTTAW) reported a net income of -$20.4M in fiscal year 2025.
What is Pasithea Therapeutics Corp's EBITDA?
Pasithea Therapeutics Corp (KTTAW) had EBITDA of -$20.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Pasithea Therapeutics Corp's return on equity (ROE)?
Pasithea Therapeutics Corp (KTTAW) has a return on equity of -37.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Pasithea Therapeutics Corp's operating cash flow?
Pasithea Therapeutics Corp (KTTAW) recorded an outflow of $15.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Pasithea Therapeutics Corp's total assets?
Pasithea Therapeutics Corp (KTTAW) had $60.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Pasithea Therapeutics Corp spend on research and development?
Pasithea Therapeutics Corp (KTTAW) invested $8.0M in research and development during fiscal year 2025.
What is Pasithea Therapeutics Corp's current ratio?
Pasithea Therapeutics Corp (KTTAW) had a current ratio of 11.35 as of fiscal year 2025, which is generally considered healthy.
What is Pasithea Therapeutics Corp's debt-to-equity ratio?
Pasithea Therapeutics Corp (KTTAW) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Pasithea Therapeutics Corp's return on assets (ROA)?
Pasithea Therapeutics Corp (KTTAW) had a return on assets of -33.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Pasithea Therapeutics Corp's cash runway?
Based on fiscal year 2025 data, Pasithea Therapeutics Corp (KTTAW) had $55.2M in cash against an annual operating cash burn of $15.2M. This gives an estimated cash runway of approximately 44 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Pasithea Therapeutics Corp's Piotroski F-Score?
Pasithea Therapeutics Corp (KTTAW) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Pasithea Therapeutics Corp's earnings high quality?
Pasithea Therapeutics Corp (KTTAW) reported a net loss of $20.4M while operations used $15.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.